Minju Gal
Chuncheon, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
TNF promotes osteoclastogenesis by secreting miR-31-5p into small extracellular vesicles via the autotaxin-LPA-LPAR1 axis in arthritic fibroblast-like synoviocytes.
Journal: Archives of biochemistry and biophysics
Published: August 31, 2025
Triterpenoids from Potentilla chinensis Inhibit RANKL-Induced Osteoclastogenesis in Vitro and Lipopolysaccharide-Induced Osteolytic Bone Loss in Vivo.
Journal: Chemistry & biodiversity
Published: August 16, 2024
Irilin D suppresses RANKL-induced osteoclastogenesis and prevents inflammation-induced bone loss by disrupting the NF-κB and MAPK signaling pathways.
Journal: European journal of pharmacology
Published: May 05, 2024
Sucrosephenylpropanoid esters and isoflavonoids isolated from Belamcanda chinensis roots and their potential anti-osteoclastogenic activity.
Journal: Bioorganic chemistry
Published: October 19, 2023
RAS‑stimulated release of exosomal miR‑494‑3p promotes the osteolytic bone metastasis of breast cancer cells.
Journal: International journal of molecular medicine
Published: March 23, 2023
Structures and antiosteoclastogenic activity of compounds isolated from edible lotus (Nelumbo nucifera Gaertn.) leaves and stems.
Journal: Fitoterapia
Published: June 08, 2022
23-Hydroxyursolic acid from Viburnum lutescens inhibits osteoclast differentiation in vitro and lipopolysaccharide-induced bone loss in vivo by suppressing c-Fos and NF-κB signalling.
Journal: International immunopharmacology
Published: May 20, 2022
Mussaendoside O, a N-triterpene cycloartane saponin, attenuates RANKL-induced osteoclastogenesis and inhibits lipopolysaccharide-induced bone loss.
Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology
Published: March 15, 2022
Showing 1-9 of 9
Last Updated: 09/26/2026